Teva Reports First Quarter 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Teva Pharma (TEVA) Tops Q1 EPS by 17c, Revenues Beat; Offers FY20 EPS/Revenue Guidance
May 7, 2020 7:05 AM EDTTeva Pharma (NYSE: TEVA) reported Q1 EPS of $0.76, $0.17 better than the analyst estimate of $0.59. Revenue for the quarter came in at $4.4 billion versus the consensus estimate of $4.15 billion.
Revenues of $4.4 billionGAAP diluted EPS of $0.06Non-GAAP diluted EPS of $0.76Free cash flow of $551 millionMr. KÃ¥re Schultz, Teva's President and CEO, said, 2020 brought an unprecedented global health crisis, affecting all nations and industries, including the pharmaceutical industry, which plays many... More
